Back to top
more

Dynavax Technologies (DVAX)

(Real Time Quote from BATS)

$11.34 USD

11.34
2,181,391

0.00 (0.00%)

Updated Apr 19, 2024 09:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Brokerage Reports

Research for DVAX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Dynavax Technologies Corporation [DVAX]

Reports for Purchase

Showing records 1 - 20 ( 121 total )

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 1

02/23/2024

Company Report

Pages: 8

4Q23 Results; 2024 Heplisav-B Sales Guidance Range Above Our Prior Estimate; Raising PT by $1

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 2

01/09/2024

Company Report

Pages: 6

2023 Heplisav-B Sales Within Guidance but Below Expectations; Several Potential Pipeline Catalysts For the Stock in 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 3

11/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for DVAX 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 4

11/03/2023

Company Report

Pages: 6

3Q23 Results; Heplisav-B Sales Continue to Impress, Raising Estimates and Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 5

10/26/2023

Company Report

Pages: 8

Recap of Dynavax at the H.C. Wainwright Annual Hepatitis B Virus Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 6

09/18/2023

Company Report

Pages: 8

Highlights From Fireside Chat With Dynavax

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 7

08/04/2023

Company Report

Pages: 6

2Q23 Results; Another Quarter of Record Heplisav-B Sales, Guidance Raised

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 8

05/03/2023

Company Report

Pages: 8

1Q23 Results; Impressive Heplisav-B Sales Exceed Expectations

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 9

02/28/2023

Daily Note

Pages: 3

Heplisav-B Receives Approval in Great Britain

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 10

02/24/2023

Company Report

Pages: 6

4Q22 Results; Record Annual Heplisav-B Sales; Lowering PT by $1 Due to Lower CpG 1018 Estimates

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 11

01/10/2023

Company Report

Pages: 6

Preliminary FY22 Commercial and Financial Highlights

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 12

11/04/2022

Company Report

Pages: 6

3Q22 Results; Heplisav-B Continues to Take Share; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 13

10/20/2022

Company Report

Pages: 7

Recap of Dynavax at the H.C. Wainwright Annual Hepatitis B Virus Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 14

09/13/2022

Daily Note

Pages: 3

Plague Vaccine Dosing Started

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 15

08/05/2022

Company Report

Pages: 8

2Q22 Results; 2Q Revenues Exceeded Expectations; Record Revenues Expected for Both Products in 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 16

05/06/2022

Company Report

Pages: 6

1Q22 Results; Heplisav-B Continues to Gain Market Share; CpG 1018 FY22 Guidance Remains at Over $550 Million in Sales

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 17

04/25/2022

Daily Note

Pages: 3

European Regulatory Update For VLA2001 COVID-19 Vaccine Adjuvanted With Dynavax''s CpG 1018

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 18

04/14/2022

Daily Note

Pages: 3

VLA2001 COVID-19 Vaccine Adjuvanted With Dynavax''s CpG 1018 Receives Conditional Marketing Authorization in the U.K.

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 19

03/01/2022

Company Report

Pages: 8

4Q21 Results; Solid Growth for Heplisav-B Expected to Continue and CpG 1018 Guidance for 2022 Above Our Expectations

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 20

01/12/2022

Company Report

Pages: 8

2022 Strategic Priorities; Phase 1 Shingles Study Initiated

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party